Final answer:
A pharmacy's reporting interval to the prescription monitoring program varies by state, but pharmaceutical sponsors must report serious and fatal drug events to the FDA within 15 days and other events quarterly.
Step-by-step explanation:
A pharmacy must report activity to the controlled substance prescription monitoring program (PMP) at varying intervals depending on the state laws and specific requirements of the PMP. However, this question seems to be confused with the reporting obligations of pharmaceutical sponsors to the FDA after New Drug Application (NDA) approval. According to the information provided, after NDA approval, a sponsor must report every patient adverse drug experience they learn of. They are required to report unexpected serious and fatal adverse drug events within 15 days, and other non-serious events on a quarterly basis through programs like MedWatch, which is a voluntary reporting system primarily for health professionals and consumers.